Using low-dose IL-2 to reduce vascular inflammation in heart attack patients
Official title: The Low-Dose Interleukin-2 For The Reduction Of Vascular Inflammation In Acute Coronary Syndromes -Clinical Outcomes And Follow-up Study
Run by Cambridge University Hospitals NHS Foundation Trust · NCT06427694 · Data updated 2026-11-12
This study is trying to see if low-dose IL-2 can help heart attack patients by reducing inflammation and preventing serious heart problems after their initial treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Cambridge University Hospitals NHS Foundation Trust Academic / other |
| Locations | 1 site (Cambridge, Cambridgeshire) |
| Status | Recruiting |
| Started | June 1, 2024 |
| Main results expected | April 30, 2027 |
| Study ends | February 11, 2030 |
| Registry record updated | June 10, 2024 |
| Trial ID | NCT06427694 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients who completed the IVORY trial and received either low-dose IL-2 or placebo.
✕Probably not a fit
Patients who declined participation in the study or were withdrawn from the IVORY trial for any reason may not receive any benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational follow-up study aims to collect cardiovascular clinical outcome data from patients who completed the IVORY trial, which investigated the effects of low-dose IL-2 on acute coronary syndromes. The study will assess major adverse cardiovascular events (MACE) such as cardiovascular death and non-fatal myocardial infarction, as well as other adverse events related to cardiovascular health. By analyzing the impact of low-dose IL-2 on inflammation and immune response, the researchers hope to better understand its potential benefits in preventing further cardiovascular complications.
Why it matters
Potential benefit: If successful, this study could lead to improved management of vascular inflammation and reduced adverse cardiovascular outcomes in patients with acute coronary syndromes.
How similar studies have gone: Other studies have shown promise in using low-dose IL-2 to modulate immune responses, but this specific follow-up approach is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who completed the full per-protocol treatment regime of low-dose IL2 or placebo having attended the final dosing visit in the IVORY trial. IVORY patients who previously consented to have their medical records inspected in the IVORY trial and who have already passed away at the commencement of IVORY-FINALE will also be included in analyses Exclusion Criteria: * Patients who decline participation * Patients who did not consent to being contacted about future research * Patients who were withdrawn from the IVORY trial for any reason
Where it's running
-
Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom Recruiting
Study contacts
- Principal investigator: Joseph Cheriyan, MBChB, FRCP — Cambridge University Hospitals NHS Foundation Trust
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI
This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.
-
Early Triple Lipid-Lowering Therapy After ACS
This trial tests whether adding bempedoic acid to high-intensity statin and ezetimibe within 72 hours after PCI helps more adults with acute coronary syndrome reach LDL-C goals than the standard two-drug approach.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
-
Early single antiplatelet therapy after IVUS-guided PCI in ACS
This study tests whether stopping aspirin early and continuing a potent P2Y12 inhibitor alone is safe and effective after IVUS-guided PCI in people with acute coronary syndrome.
-
Local and systemic macrophage activation in coronary and peripheral artery disease
This study tests whether macrophage activity inside coronary and peripheral arteries relates to circulating monocyte subtypes in people with stable and acute artery disease.
-
Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty
This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.